295 related articles for article (PubMed ID: 21147950)
1. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer.
Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
J Clin Microbiol; 2011 Feb; 49(2):557-64. PubMed ID: 21147950
[TBL] [Abstract][Full Text] [Related]
2. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.
Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
J Clin Microbiol; 2010 Aug; 48(8):2779-85. PubMed ID: 20573862
[TBL] [Abstract][Full Text] [Related]
3. Performance of ProEx C and PreTect HPV-Proofer E6/E7 mRNA tests in comparison with the hybrid capture 2 HPV DNA test for triaging ASCUS and LSIL cytology.
Alaghehbandan R; Fontaine D; Bentley J; Escott N; Ghatage P; Lear A; Coutlee F; Ratnam S
Diagn Cytopathol; 2013 Sep; 41(9):767-75. PubMed ID: 23341349
[TBL] [Abstract][Full Text] [Related]
4. Quantivirus® HPV E6/E7 RNA 3.0 assay (bDNA) is as sensitive, but less specific than Hybrid Capture 2 test.
Shen Y; Gong J; He Y; Cheng G; Okunieff P; Li X
J Virol Methods; 2013 Feb; 187(2):288-93. PubMed ID: 23201290
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test.
Benevolo M; Vocaturo A; Caraceni D; French D; Rosini S; Zappacosta R; Terrenato I; Ciccocioppo L; Frega A; Giorgi Rossi P
J Clin Microbiol; 2011 Jul; 49(7):2643-50. PubMed ID: 21525231
[TBL] [Abstract][Full Text] [Related]
6. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.
Rijkaart DC; Heideman DA; Coupe VM; Brink AA; Verheijen RH; Skomedal H; Karlsen F; Morland E; Snijders PJ; Meijer CJ
J Clin Microbiol; 2012 Jul; 50(7):2390-6. PubMed ID: 22553244
[TBL] [Abstract][Full Text] [Related]
7. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens.
Keegan H; Mc Inerney J; Pilkington L; Grønn P; Silva I; Karlsen F; Bolger N; Logan C; Furuberg L; O'Leary J; Martin C
J Virol Methods; 2009 Jan; 155(1):61-6. PubMed ID: 18955086
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the clinical performance of an HPV mRNA test and an HPV DNA test in triage of atypical squamous cells of undetermined significance (ASC-US).
Waldstrom M; Ornskov D
Cytopathology; 2012 Dec; 23(6):389-95. PubMed ID: 21933290
[TBL] [Abstract][Full Text] [Related]
9. Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions.
Virtanen E; Kalliala I; Dyba T; Nieminen P; Auvinen E
Acta Obstet Gynecol Scand; 2017 Jan; 96(1):61-68. PubMed ID: 27858961
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Aptima and hybrid capture-2 HPV tests and Pap test in the referral population in Japan.
Kuroki H; Sakamoto J; Shibata T; Takakura M; Sasagawa T
J Med Virol; 2021 Aug; 93(8):5076-5083. PubMed ID: 33634473
[TBL] [Abstract][Full Text] [Related]
11. Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types.
Giorgi Rossi P; Bisanzi S; Allia E; Mongia A; Carozzi F; Gillio-Tos A; De Marco L; Ronco G; Gustinucci D; Del Mistro A; Frayle H; Iossa A; Fantacci G; Pompeo G; Cesarini E; Bulletti S; Passamonti B; Rizzi M; Penon MG; Barca A; Benevolo M
J Clin Microbiol; 2017 Apr; 55(4):1056-1065. PubMed ID: 28100595
[TBL] [Abstract][Full Text] [Related]
12. [HPV E6 and E7 mRNA combined with HPV 16 and 18 or 45 genotyping testing as a means of cervical cancer opportunistic screening].
Wang JJ; Dong J; Deng ZX; Wang PF; Zhang XX; Du Y
Zhonghua Fu Chan Ke Za Zhi; 2019 May; 54(5):301-306. PubMed ID: 31154710
[No Abstract] [Full Text] [Related]
13. Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers.
Basu P; Banerjee D; Mittal S; Dutta S; Ghosh I; Chowdhury N; Abraham P; Chandna P; Ratnam S
J Med Virol; 2016 Jul; 88(7):1271-8. PubMed ID: 26693677
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany.
Iftner T; Neis KJ; Castanon A; Landy R; Holz B; Woll-Herrmann A; Iftner A; Staebler A; Wallwiener D; Hann von Weyhern C; Neis F; Haedicke-Jarboui J; Martus P; Brucker S; Henes M; Sasieni P
J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355760
[TBL] [Abstract][Full Text] [Related]
15. Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany.
Iftner T; Becker S; Neis KJ; Castanon A; Iftner A; Holz B; Staebler A; Henes M; Rall K; Haedicke J; von Weyhern CH; Clad A; Brucker S; Sasieni P
J Clin Microbiol; 2015 Aug; 53(8):2509-16. PubMed ID: 26019212
[TBL] [Abstract][Full Text] [Related]
16. Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions.
Dockter J; Schroder A; Hill C; Guzenski L; Monsonego J; Giachetti C
J Clin Virol; 2009 Jul; 45 Suppl 1():S55-61. PubMed ID: 19651370
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples.
Liu TY; Xie R; Luo L; Reilly KH; He C; Lin YZ; Chen G; Zheng XW; Zhang LL; Wang HB
J Virol Methods; 2014 Feb; 196():120-5. PubMed ID: 24216236
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I.
Wu R; Belinson SE; Du H; Na W; Qu X; Wu R; Liu Y; Wang C; Zhou Y; Zhang L; Belinson JL
Int J Gynecol Cancer; 2010 Nov; 20(8):1411-4. PubMed ID: 21051986
[TBL] [Abstract][Full Text] [Related]
19. Clinical performance of a human papillomavirus messenger RNA test (Aptima HPV Assay) on residual material from archived 3-year-old PreservCyt samples with low-grade squamous intraepithelial lesion.
Waldstrøm M; Ornskov D
Arch Pathol Lab Med; 2011 Aug; 135(8):1052-6. PubMed ID: 21809999
[TBL] [Abstract][Full Text] [Related]
20. Clinical Value of Human Papillomavirus E6/E7 mRNA Detection in Screening for Cervical Cancer in Women Positive for Human Papillomavirus DNA or.
Han L; Husaiyin S; Zhao F; Rezhake R; Niyazi M
Clin Lab; 2018 Sep; 64(9):1363-1371. PubMed ID: 30274003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]